Association of institutional masking policies with healthcare-associated SARS-CoV-2 infections in Swiss acute care hospitals during the BA.4/5 wave (CH-SUR study): a retrospective observational study.


Journal

Antimicrobial resistance and infection control
ISSN: 2047-2994
Titre abrégé: Antimicrob Resist Infect Control
Pays: England
ID NLM: 101585411

Informations de publication

Date de publication:
18 Jun 2024
Historique:
received: 06 02 2024
accepted: 05 06 2024
medline: 18 6 2024
pubmed: 18 6 2024
entrez: 17 6 2024
Statut: epublish

Résumé

In the initial phase of the SARS-CoV-2 pandemic, masking has been widely accepted in healthcare institutions to mitigate the risk of healthcare-associated infection. Evidence, however, is still scant and the role of masks in preventing healthcare-associated SARS-CoV-2 acquisition remains unclear.We investigated the association of variation in institutional mask policies with healthcare-associated SARS-CoV-2 infections in acute care hospitals in Switzerland during the BA.4/5 2022 wave. SARS-CoV-2 infections in hospitalized patients between June 1 and September 5, 2022, were obtained from the "Hospital-based surveillance of COVID-19 in Switzerland"-database and classified as healthcare- or community-associated based on time of disease onset. Institutions provided information regarding institutional masking policies for healthcare workers and other prevention policies. The percentage of healthcare-associated SARS-CoV-2 infections was calculated per institution and per type of mask policy. The association of healthcare-associated SARS-CoV-2 infections with mask policies was tested using a negative binominal mixed-effect model. We included 2'980 SARS-CoV-2 infections from 13 institutions, 444 (15%) were classified as healthcare-associated. Between June 20 and June 30, 2022, six (46%) institutions switched to a more stringent mask policy. The percentage of healthcare-associated infections subsequently declined in institutions with policy switch but not in the others. In particular, the switch from situative masking (standard precautions) to general masking of HCW in contact with patients was followed by a strong reduction of healthcare-associated infections (rate ratio 0.39, 95% CI 0.30-0.49). In contrast, when compared across hospitals, the percentage of health-care associated infections was not related to mask policies. Our findings suggest switching to a more stringent mask policy may be beneficial during increases of healthcare-associated SARS-CoV-2 infections at an institutional level.

Sections du résumé

BACKGROUND BACKGROUND
In the initial phase of the SARS-CoV-2 pandemic, masking has been widely accepted in healthcare institutions to mitigate the risk of healthcare-associated infection. Evidence, however, is still scant and the role of masks in preventing healthcare-associated SARS-CoV-2 acquisition remains unclear.We investigated the association of variation in institutional mask policies with healthcare-associated SARS-CoV-2 infections in acute care hospitals in Switzerland during the BA.4/5 2022 wave.
METHODS METHODS
SARS-CoV-2 infections in hospitalized patients between June 1 and September 5, 2022, were obtained from the "Hospital-based surveillance of COVID-19 in Switzerland"-database and classified as healthcare- or community-associated based on time of disease onset. Institutions provided information regarding institutional masking policies for healthcare workers and other prevention policies. The percentage of healthcare-associated SARS-CoV-2 infections was calculated per institution and per type of mask policy. The association of healthcare-associated SARS-CoV-2 infections with mask policies was tested using a negative binominal mixed-effect model.
RESULTS RESULTS
We included 2'980 SARS-CoV-2 infections from 13 institutions, 444 (15%) were classified as healthcare-associated. Between June 20 and June 30, 2022, six (46%) institutions switched to a more stringent mask policy. The percentage of healthcare-associated infections subsequently declined in institutions with policy switch but not in the others. In particular, the switch from situative masking (standard precautions) to general masking of HCW in contact with patients was followed by a strong reduction of healthcare-associated infections (rate ratio 0.39, 95% CI 0.30-0.49). In contrast, when compared across hospitals, the percentage of health-care associated infections was not related to mask policies.
CONCLUSIONS CONCLUSIONS
Our findings suggest switching to a more stringent mask policy may be beneficial during increases of healthcare-associated SARS-CoV-2 infections at an institutional level.

Identifiants

pubmed: 38886813
doi: 10.1186/s13756-024-01422-4
pii: 10.1186/s13756-024-01422-4
doi:

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

64

Subventions

Organisme : Schweizerische Akademie der Medizinischen Wissenschaften
ID : YTCR 12/22

Informations de copyright

© 2024. The Author(s).

Références

Infect Control Hosp Epidemiol. 2022 Jun;43(6):757-763
pubmed: 33934743
Clin Invest Med. 2021 Jun 14;44(2):E48-54
pubmed: 34152707
N Engl J Med. 2023 Jul 6;389(1):4-6
pubmed: 37314330
J Health Econ. 2022 Mar;82:102592
pubmed: 35104669
Zhonghua Liu Xing Bing Xue Za Zhi. 2004 Jan;25(1):18-22
pubmed: 15061941
Infect Dis Poverty. 2020 Jul 23;9(1):104
pubmed: 32703281
Am J Dis Child. 1981 Jun;135(6):512-5
pubmed: 7234784
Clin Infect Dis. 2021 Nov 2;73(9):1693-1695
pubmed: 33704451
J Infect Dev Ctries. 2020 Nov 30;14(11):1231-1237
pubmed: 33296333
Lancet. 2003 May 3;361(9368):1519-20
pubmed: 12737864
Infect Control Hosp Epidemiol. 2020 Dec;41(12):1466-1467
pubmed: 32576336
Ann Intern Med. 2020 Oct 6;173(7):542-555
pubmed: 32579379
Occup Med (Lond). 2020 Dec 12;70(8):606-609
pubmed: 33225363
Ann Intern Med. 2023 Jun;176(6):859-861
pubmed: 37068281
Influenza Other Respir Viruses. 2016 Jul;10(4):268-90
pubmed: 26901358
Psychiatry Res. 2021 Aug;302:114036
pubmed: 34098157
Influenza Other Respir Viruses. 2017 Nov;11(6):511-517
pubmed: 28799710
Elife. 2020 May 11;9:
pubmed: 32392129
J Hosp Infect. 2022 Feb;120:81-84
pubmed: 34861313
PLoS Med. 2021 Oct 12;18(10):e1003816
pubmed: 34637439
Swiss Med Wkly. 2021 Feb 15;151:w20475
pubmed: 33638351
BMC Pulm Med. 2019 Oct 30;19(1):190
pubmed: 31666061
JAMA. 2020 Aug 18;324(7):703-704
pubmed: 32663246
J Hosp Infect. 2023 Apr;134:108-120
pubmed: 36738991
J Occup Environ Med. 2021 Jun 1;63(6):476-481
pubmed: 33596025
J Hosp Infect. 2022 Mar;121:82-90
pubmed: 34929232
JAMA Netw Open. 2022 Aug 1;5(8):e2226816
pubmed: 35969403

Auteurs

Tamara Dörr (T)

Division of Infectious Diseases, Infection Prevention and Travel Medicine, Cantonal Hospital St Gallen, Rorschacher Strasse 95, St. Gallen, CH-9007, Switzerland.

Sabine Güsewell (S)

Division of Infectious Diseases, Infection Prevention and Travel Medicine, Cantonal Hospital St Gallen, Rorschacher Strasse 95, St. Gallen, CH-9007, Switzerland.

Domenica Flury (D)

Division of Infectious Diseases, Infection Prevention and Travel Medicine, Cantonal Hospital St Gallen, Rorschacher Strasse 95, St. Gallen, CH-9007, Switzerland.

Maria Süveges (M)

Faculté de Médecine de l'Université de Genève, Institut de Santé Globale, 24 rue du Général- Dufour, Genève 4, 1211, Switzerland.

Camille Beatrice Gaza Valera (CB)

Faculté de Médecine de l'Université de Genève, Institut de Santé Globale, 24 rue du Général- Dufour, Genève 4, 1211, Switzerland.

Sara Botero-Mesa (S)

Faculté de Médecine de l'Université de Genève, Institut de Santé Globale, 24 rue du Général- Dufour, Genève 4, 1211, Switzerland.

Marie-Céline Zanella (MC)

Service de prévention et contrôle de l'infection, Direction médicale et qualité, Hôpitaux universitaires Genève, Rue Gabrielle-Perret-Gentil 4, Genève, 1205, Switzerland.
Infection Control Program and WHO Collaborating Centre on Patient Safety, Geneva University Hospitals and Faculty of Medicine, Rue Gabrielle-Perret-Gentil 4, Genève, 1205, Switzerland.

Anne Iten (A)

Service de prévention et contrôle de l'infection, Direction médicale et qualité, Hôpitaux universitaires Genève, Rue Gabrielle-Perret-Gentil 4, Genève, 1205, Switzerland.

Carlo Balmelli (C)

Infection Control Programme, EOC Hospitals, Viale Officina 3, Bellinzona, 6500, Switzerland.

Nicolas Troillet (N)

Service of Infectious Diseases, Central Institute, Valais Hospitals, Av. Grand-Champsec 80, Sion, 1951, Switzerland.

Sarah Tschudin-Sutter (S)

Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel and University of Basel, Petersgraben 4, Basel, 4031, Switzerland.

Peter W Schreiber (P)

Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich and University of Zurich, Raemistrasse 100, Zurich, 8091, Switzerland.

Philipp Jent (P)

Department of Infectious Diseases, Bern University Hospital (Inselspital), University of Bern, Länggassstrasse 122, Bern, 3012, Switzerland.

Lauro Damonti (L)

Department of Infectious Diseases, Bern University Hospital (Inselspital), University of Bern, Länggassstrasse 122, Bern, 3012, Switzerland.

Rami Sommerstein (R)

Department of Infectious Diseases, Bern University Hospital (Inselspital), University of Bern, Länggassstrasse 122, Bern, 3012, Switzerland.
Faculty of Health Sciences and Medicine, Clinic St. Anna, University of Lucerne, Alpenquai 4, Lucerne, 6005, Switzerland.

Lea Portmann (L)

Faculty of Health Sciences and Medicine, Clinic St. Anna, University of Lucerne, Alpenquai 4, Lucerne, 6005, Switzerland.

Danielle Vuichard-Gysin (D)

Department of Infectious Diseases, Thurgau Cantonal Hospital, Spitalcampus 1, Muensterlingen, 8596, Switzerland.

Alexia Cusini (A)

Department of Infectious Diseases, Cantonal Hospital Graubuenden, Loëstrasse 170, Chur, 7000, Switzerland.

Yvonne Nussbaumer-Ochsner (Y)

Klinik für Innere Medizin, Kantonsspital Spitäler Schaffhausen, Geissbergstrasse 81, Schaffhausen, 8208, Switzerland.

Ulrich Heininger (U)

Infectious Diseases and Vaccinology, University of Basel Children's Hospital, Spitalstrasse 33, Basel, 4056, Switzerland.

Christoph Berger (C)

Division of Infectious Diseases and Children's Research Centre, University Children's Hospital Zurich, Steinwiesstrasse 75, Zurich, 8032, Switzerland.

Petra Zimmermann (P)

Department of Community Health, Faculty of Science and Medicine, University of Fribourg, Chemin du Musée 8, Fribourg, 1700, Switzerland.
Department of Paediatrics, Fribourg Hospital HFR, Chemin des Pensionnats 2-6, Fribourg, Villars-sur-Glâne, 1752, Switzerland.

Céline Gardiol (C)

Swiss Federal Office of Public Health, Schwarzenburgstrasse 157, Bern, 3003, Switzerland.

Olivia Keiser (O)

Faculté de Médecine de l'Université de Genève, Institut de Santé Globale, 24 rue du Général- Dufour, Genève 4, 1211, Switzerland.

Matthias Schlegel (M)

Division of Infectious Diseases, Infection Prevention and Travel Medicine, Cantonal Hospital St Gallen, Rorschacher Strasse 95, St. Gallen, CH-9007, Switzerland.

Philipp Kohler (P)

Division of Infectious Diseases, Infection Prevention and Travel Medicine, Cantonal Hospital St Gallen, Rorschacher Strasse 95, St. Gallen, CH-9007, Switzerland.

Stefan P Kuster (S)

Division of Infectious Diseases, Infection Prevention and Travel Medicine, Cantonal Hospital St Gallen, Rorschacher Strasse 95, St. Gallen, CH-9007, Switzerland. stefan.kuster@kssg.ch.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH